Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Epiphany Biosciences

Epiphany Biosciences
2006 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$36.2M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of antiviral therapeutics to to prevent the spread of varicella zoster virus (VZV), epstein-barr virus (EBV) and hepatitis C virus (HCV).

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • One California Street
  • Suite 2800
  • San Francisco, CA 94111
  • United States

+1 (415) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Epiphany Biosciences’s full profile, request a free trial.

Epiphany Biosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 14-Mar-2007 $36.2M 000.00 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Epiphany Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Epiphany Biosciences Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
CDIB BioScience Venture Management Venture Capital Minority 000 0000 000000 0
Global Trust Ventures PE/Buyout Minority 000 0000 000000 0
Wexford Capital Hedge Fund Minority 000 0000 000000 0
Windsor Bay Capital Other Minority 000 0000 000000 0

Epiphany Biosciences Executive Team (4)

Name Title Board
Seat
Contact
Info
Fred Volinsky MD Chief Executive Officer, Co-Founder and Chairman
Michael Houghton Chief Scientific Officer
Brian Murphy Chief Medical Officer
Steve Blank Co-Founder